Could Delivra Corp Change Direction After Today’s Huge Increase?

 Could Delivra Corp Change Direction After Today's Huge Increase?

The stock of Delivra Corp (CVE:DVA) is a huge mover today! About 292,939 shares traded hands or 932.89% up from the average. Delivra Corp (CVE:DVA) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
The move comes after 9 months positive chart setup for the $13.82 million company. It was reported on Nov, 30 by We have $0.65 PT which if reached, will make CVE:DVA worth $1.24 million more.

More notable recent Delivra Corp (CVE:DVA) news were published by: which released: “Delivra Corp. Issues $2020900, 6% Unsecured Convertible Debentures” on September 15, 2016, also with their article: “Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis …” published on September 19, 2016, published: “Delivra Announces Q2 2016 Financial Results” on August 29, 2016. More interesting news about Delivra Corp (CVE:DVA) were released by: and their article: “Delivra Enhances Performance of Celebrex(TM) (Celecoxib) — New Formulation …” published on October 03, 2016 as well as‘s news article titled: “Delivra Powers Diabetic Wound Healing” with publication date: March 29, 2016.

Delivra Corp., formerly Whiteknight Acquisitions III Inc., is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin. The company has a market cap of $13.82 million. The Firm makes and sells natural topical creams under its brand names, LivRelief, which is indicated for conditions, including joint and muscle pain, nerve pain, circulation and wound healing, and LivSport brand, which is indicated for sports performance. It currently has negative earnings. The Company’s business is divided into two areas of focus: Consumer Healthcare Over the Counter Retail products, and Technology Licensing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment